Sonnet BioTherapeutics Holdings, Inc. (SONN) is lower by Wednesday morning, with the stock decreasing -26.52% in pre-market trading to 1.33.
SONN's short-term technical score of 14 indicates that the stock has traded less bullishly over the last month than 86% of stocks on the market. In the Biotechnology industry, which ranks 137 out of 146 industries, Sonnet BioTherapeutics Holdings, Inc. ranks higher than 28% of stocks.
Sonnet BioTherapeutics Holdings, Inc. has fallen 41.04% over the past month, closing at $2.86 on September 27. During this period of time, the stock fell as low as $2.02 and as high as $2.97. SONN has an average analyst recommendation of Strong Buy. The company has an average price target of $111.14.
SONN has an Overall Score of 51. Find out what this means to you and get the rest of the rankings on SONN!
Sonnet BioTherapeutics Holdings, Inc. has a Long-Term Technical rank of 69. This means that trading over the last 200 trading days has placed the company in the upper half of stocks with 31% of the market scoring higher. In the Biotechnology industry which is number 133 by this metric, SONN ranks better than 133% of stocks.
